Biogen enrolls patients in new MS trial - Boston Business Journal:

http://www.tl-edu.net/Heros-And-Who-We-Are.html
The trial, called ADVANCE, will determine the efficacty and safetyof Biogen’s drug called PEGylated interferon beta-1a, in reducing relapses rates in patients with multiple sclerosis (RMS). The global studyg will enroll morethan 1,200 patients with RMS betweenj the ages of 18 and 55. The study’s goal is to determinew whether the drug reduces the annualized relapse rate in patientse with RMS at one The study will alsoexamine if, over the potential treatment can slow disease progression and lead to a decreasr in the number of a certain kind of brai n lesions commonly seen in MS The treatment is a combination of Interferon beta-1a, whichg has been used successfully to treat MS for more than 10 and PEGylation, which can extend the amoungt of time a drug remains in a patient’zs system.
If the trial is successful, the treatment has the potentiall to reduce the frequency of treatment injectione and provide patients with an effective and more convenienttdosing option. Biogen’s (NASDAQ: BIIB) stock was tradingy at in $49.33 in morning trading on down from the previous closesof $51.67.